The influence of lung surfactant liquid crystalline nanostructures on respiratory drug delivery
详细信息 查看全文
- 作者：Shyamal C. Dasa ; shyamal.das@otago.ac.nz" class="auth_mail" title="E-mail the corresponding author ; shyamal569@yahoo.com" class="auth_mail" title="E-mail the corresponding author ; Peter J. Stewartb
- 关键词：API ; active pharmaceutical ingredient ; CI ; cubic phase ; CII ; inverse bi-continuous cubic phase ; DPPC ; 1 ; 2 dipalmitoyl phosphatidylcholine ; HI ; hexagonal phase ; HII ; inverse hexagonal phase ; IPAC &ndash ; RS ; International Pharmaceutical Aerosol Consortium on Regulation and Science ; Lα ; lamellar liquid crystalline phase ; LI ; micelles ; LII ; inverse micelles ; LS ; lung surfactant ; 99mTc-DTPA ; 99mTc-diethylene triamine penta acetate ; PC ; phosphatidylcholines ; PE ; phosphatidyl ethanolamine ; PG ; phosph
- 刊名：International Journal of Pharmaceutics
- 出版年：2016
- 出版时间：5 December 2016
- 年：2016
- 卷：514
- 期：2
- 页码：465-474
- 全文大小：2749 K
文摘
- •
Lung surfactant may form different liquid crystalline phases.
- •
Liquid crystalline nanostructures may have potential roles in defining the dissolution mechanism and rate.
- •
Liquid crystalline nanostructures might be changed to influence delivery and induce toxicity.